Varivax

Varivax is a live, attenuated varicella vaccine derived from the Oka/Merck strain, designed to protect against chickenpox. This vaccine is produced in human diploid cells and is administered via injection. It helps build immunity to the varicella-zoster virus.

Varivax is used to prevent chickenpox (varicella) in individuals who have not had the disease or been previously vaccinated. It is recommended for children, adolescents, and adults without evidence of immunity. The vaccine works by exposing the body to a weakened form of the virus, prompting the immune system to produce antibodies.

After administration, Varivax may cause mild effects such as redness, swelling, or pain at the injection site. Some individuals may experience a low-grade fever or mild rash resembling chickenpox. These effects are generally temporary and indicate the body’s immune response.

Varivax should not be used in individuals with a severe allergic reaction to any component of the vaccine or to neomycin. It is important to inform your healthcare provider of any allergies, fever, or immune system disorders before vaccination. Pregnant individuals should avoid receiving Varivax.

Varivax may interact with other vaccines or medications that suppress the immune system, such as corticosteroids or chemotherapy. Blood products or immune globulins may reduce the vaccine’s effectiveness. It is recommended to separate live vaccines by at least 4 weeks if not administered simultaneously.